News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Applied Data Research: Transdermal Drug Delivery for CNS Conditions Expected to Exceed $1 Billion by 2012


5/27/2009 10:11:50 AM

(Nashua, NH) – While often overshadowed in the public consciousness by cancer and heart disease, recent trends in certain pathologies of the central nervous system are becoming equally challenging for clinicians and researchers. Growth in the incidence of a number of neurological conditions such as Alzheimer’s and Parkinson’s has captured the concerns of healthcare professionals, and reached the public at large through personal experience and the media.

While some of the increase in the incidence of non-neoplastic CNS disorders can be traced to population growth and demographic trends, particularly the aging of populations in developed geographic regions, often the specific causes prove to be elusive. And while patient mortality varies widely within this group of conditions, the morbidity and quality-of-life issues for patients and their families with chronic or progressive CNS disorders are typically quite dramatic.

“The intractable nature of these diseases dictates the need for continuous drug intervention,” explains George Perros, Managing Director at Applied Data Research. “But the treatment picture is complicated by the fact that most of these ailments compromise the cognitive and/or motor skills of patients, making ongoing self-administration unreliable and raising patient safety concerns.”

Attempting to address this growing need, drug developers are increasingly turning to transdermal formulations of CNS drugs. Because it has the potential to improve drug therapy compliance and safety, transdermal delivery addresses key therapeutic healthcare issues. According to a comprehensive assessment by Applied Data Research, the ability of transdermal CNS therapeutics to respond to the growing unmet need for patient-friendly administration has positioned this segment for healthy double-digit growth through 2012, with the total value of transdermal CNS drug products exceeding $1 billion in 2012.

These findings are contained in a comprehensive report prepared and written by Applied Data Research. More information is available at www.applieddata.org.

About Applied Data

Applied Data Research is a healthcare therapeutics consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES